AVIEW LCS vs uOmnispace.MI
AI Verdict
Choose AVIEW LCS if…
Choose AVIEW LCS if your primary need is an AI-powered solution specifically designed for comprehensive lung cancer screening and cardiopulmonary assessment using low-dose CT scans. This tool excels in automating nodule detection, Lung-RADS classification, and quantifying emphysema and coronary artery calcification, streamlining workflows for early disease detection and follow-up.
View AVIEW LCS →Choose uOmnispace.MI if…
Choose uOmnispace.MI if your facility requires a versatile, advanced medical imaging software capable of comprehensive 2D and 3D viewing and AI-enhanced segmentation across multiple modalities like PET, CT, MR, and SPECT. This platform is ideal for complex cases in oncology, neurology, and cardiology that demand multi-user access, image registration, fusion imaging, and detailed quantitative analysis across various anatomical regions.
View uOmnispace.MI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW LCS | uOmnispace.MI |
|---|---|---|
| Pricing | Contact for pricing | Contact vendor |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Software-only medical device; can be stand-alone or integrated; compatible with off-the-shelf PCs; supports SaaS, on-premise, and hybrid models. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEW LCSAVIEW LCS emphasizes 'fully automatic analysis' and 'streamlining radiology workflows' for lung nodule detection, COPD, and coronary artery calcification. Its automated reporting and comparison features are designed to reduce manual effort and enhance efficiency in specific screening tasks, suggesting higher usability for its target applications.
Clinical Value
AVIEW LCSAVIEW LCS explicitly claims to enhance diagnostic accuracy for lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan, providing specific, quantifiable metrics like Lung-RADS classification, nodule volume, emphysema quantification, and CAC scoring. This focused approach with validated metrics offers direct and measurable clinical value for its specialized applications.
Pricing & Value
TieBoth tools require direct contact for pricing information, and no public data on their cost or specific return on investment (ROI) studies are available. Therefore, it is impossible to conduct a head-to-head comparison of their pricing and overall value proposition.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being HIPAA compliant, FDA cleared, and offering flexible deployment options including cloud, hybrid, and on-premise solutions. AVIEW LCS integrates with PACS/RIS, while uOmnispace.MI supports remote multi-user access and compatibility with off-the-shelf PCs, making both well-suited for diverse enterprise environments.
Innovation
AVIEW LCSAVIEW LCS stands out for its integrated, fully automatic analysis of multiple thoracic diseases (lung cancer, COPD, and coronary artery calcification) from a single low-dose CT scan, and automated comparison of nodules in follow-up scans. This comprehensive, automated, and longitudinal assessment from a single input represents a significant innovation in streamlining and enhancing population-level screening programs.
Support & Docs
uOmnispace.MIUnited Imaging Healthcare (Tool B) provides a more extensive and detailed support infrastructure, including a 'United Performance Guarantee' for uptime, a typical response time of less than 4 hours, and comprehensive training for in-house biomedical engineers. They also offer 'White-Glove Support' and 24/7 remote monitoring, indicating a robust and formalized global support system.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW LCS | uOmnispace.MI |
|---|---|---|
| Name | AVIEW LCS | uOmnispace.MI |
| Company | Coreline Soft Co. | Shanghai United Imaging Healthcare Co. |
| Primary AI Focus/Categories | Cardiology AI, Oncology AI, Radiology & Imaging AI (specifically lung cancer screening, COPD, coronary artery calcification) | Cardiology AI, Neurology AI, Oncology AI (general 2D/3D viewing, AI-enhanced segmentation across PET, CT, MR, SPECT) |
| Specific AI-Powered Analysis | Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Emphysema quantification (LAA index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass), Automated comparison of nodules in follow-up CT scans, Comprehensive, automated report generation. | Manual and automatic segmentation (including AI-based rib extraction), Image registration and lesion segmentation, Quantitative analysis and fusion imaging, Dynamic PET data analysis. |
| Supported Imaging Modalities | Low-dose CT scan | PET, CT, MR, and SPECT images |
Videos
Demos, reviews, and walkthroughs featuring AVIEW LCS and uOmnispace.MI.